Media Update: Dupixent® (dupilumab) U.S. label updated with data further supporting use in atopic dermatitis with moderate-to-severe hand and foot involvement

https://ift.tt/s0lOVQM

from Sanofi - Aventis Groupe https://ift.tt/CLPUQ4n
via IFTTT